Atezolizumab–Bevacizumab in HCC - Real-World Benefit Extends Beyond Two Years: Hepatology | September 2026

Introduction:

Atezolizumab plus bevacizumab (Atezo–Bev) transformed first-line treatment of unresectable hepatocellular carcinoma (HCC), but long-term follow-up from the pivotal IMbrave150 trial was limited. The prospective Italian ARTE study provides important real-world evidence on long-term survival, safety, hepatic decompensation, and opportunities for subsequent curative-intent treatment.

Why was this study needed?

Long-term outcomes with Atezo–Bev remain incompletely characterised.

Real-world HCC populations are more heterogeneous than clinical trial cohorts.

Tumor response alone may not capture outcomes because liver function and decompensation remain competing determinants of survival.

Increasing tumour responses raise the possibility of subsequent surgery or locoregional therapy.

Results:

Among 538 patients, median overall survival was approximately 20 months, with 30% alive at 3 years.

Tumor response, progression, and importantly liver decompensation strongly influenced survival.

Severe adverse events occurred in about one-third of patients, but no new long-term safety signal emerged.

Approximately 15% underwent surgery or locoregional treatment after starting Atezo–Bev, and a small but clinically important group ultimately achieved drug-free, disease-free status.

Clinical Impact:

Atezo–Bev should increasingly be viewed as part of a dynamic multidisciplinary HCC strategy, rather than simply continuous systemic therapy until progression. Patients achieving substantial tumour response should be repeatedly reassessed for resection, ablation, or other locoregional approaches.

Equally important, preservation of hepatic reserve remains central: decompensation can compromise survival independently of tumor progression.

Bottom Line:

Real-world Atezo–Bev provides durable benefit in unresectable HCC, with nearly one-third of patients alive at 3 years. The emerging paradigm is broader than systemic therapy alone—preserve liver function, assess response continuously, and actively look for opportunities to convert selected responders to definitive locoregional or surgical treatment.